Abstract:Broadly neutralizing antibodies (bnAbs) targeting the receptor binding site (RBS) of hemagglutinin (HA) have potential for developing into powerful anti-influenza agents. Several previously reported influenza B bnAbs are nevertheless unable to neutralize a portion of influenza B virus variants. HA-specific bnAbs with hemagglutination inhibition (HI) activity may possess the ability to block virus entry directly. Polymeric IgM antibodies are expected to more effectively inhibit virus attachment and entry into target cells due to their higher avidity and/or steric hindrance. We therefore hypothesized that certain RBS-targeted IgM antibodies with strong cross-lineage HI activity might display broader and more potent antiviral activity against rapidly evolving influenza B viruses. Methods: In this study, we generated IgM and IgG bnAbs targeting the RBS of influenza B virus using the murine hybridoma technique. IgM and IgG versions of the same antibodies were then developed by isotype switching and characterized in subsequent in vitro and in vivo experiments. Results: Two IgM and two IgG bnAbs against influenza B virus HA were identified. Of these, one IgM subtype antibody, C7G6-IgM, showed strong HI and neutralization activities against all 20 representative influenza B strains tested, with higher potency and broader breadth of anti-influenza activity in vitro than the IgG subtype variant of itself, or other previously-reported influenza B bnAbs. Furthermore, C7G6-IgM conferred excellent cross-protection against distinct lineages of influenza B viruses in mice and ferrets, performing better than the anti-influenza drug oseltamivir, and showed an additive antiviral effect when administered in combination with oseltamivir. Mechanistically, C7G6-IgM potently inhibits infection with influenza B virus strains from different lineages by blocking viral entry. Conclusion: In summary, our study highlights the potential of IgM subtype antibodies in combatting pathogenic microbes. Moreover, C7G6-IgM is a promising candidate for the development of prophylactics or therapeutics against influenza B infection.

A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses

A Broadly Protective Therapeutic Antibody Against Influenza B Virus with Two Mechanisms of Action

An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies.

Broadly neutralizing antibodies recognizing different antigenic epitopes act synergistically against the influenza B virus.

Identification of a cross-neutralizing antibody that targets the receptor binding site of H1N1 and H5N1 influenza viruses

Universal antibody targeting the highly conserved fusion peptide provides cross-protection in mice

An IgM Antibody Targeting the Receptor Binding Site of Influenza B Blocks Viral Infection with Great Breadth and Potency

Evaluation of Panel of Neutralising Murine Monoclonal Antibodies and a Humanised Bispecific Antibody Against Influenza A(H1N1)pdm09 Virus Infection in a Mouse Model.

Isolation of human antibodies against influenza B neuraminidase and mechanisms of protection at the airway interface

Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses

A small-molecule fusion inhibitor of influenza virus is orally active in mice

Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase

An armed anti-immunoglobulin light chain nanobody protects mice against influenza A and B infections

Broadly protective human antibodies that target the active site of influenza virus neuraminidase

Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes.

A new class of antibodies that overcomes a steric barrier to cross-group neutralization of influenza viruses

A recombinant protein containing influenza viral conserved epitopes and superantigen induces broad-spectrum protection

A pan-influenza antibody inhibiting neuraminidase via receptor mimicry

CD388: A universally protective Drug-Fc Conjugate that targets influenza virus neuraminidase

Dual neutralization of influenza virus hemagglutinin and neuraminidase by a bispecific antibody leads to improved antiviral activity

Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody